Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Understanding Ohio X-Waivered Advanced Practice Registered Nurses’ Rate of Naltrexone Prescription for Alcohol Use Disordered Patients

Understanding Ohio X-Waivered Advanced Practice Registered Nurses’ Rate of Naltrexone... Background:Alcohol use disorder (AUD) is overrepresented within the United States. Naltrexone, a recommended treatment for AUD, is underutilized. However, the prescribing behaviors of advanced practice registered nurses (APRNs) regarding naltrexone for AUD patients have not been studied. The purpose of our study was to explore the prescriptive practices of a sample of APRNs.Aims:To describe and analyze survey responses of a sample of Ohio APRNs with training in medication for addiction treatment (MAT) for substance use disorders (as evidenced by DEA x-waiver receipt) regarding prescribing practices of naltrexone for AUD patients.Method:Public information collected from the first author’s Nursing Board (list of APRNs in Ohio) was checked against the public information of x-waivered providers nationally from the Substance Abuse and Mental Health Services Administration’s (SAMHSA) website. This generated a potential sample size of 824 APRNs, all of whom were sent email solicitations to complete a Qualtrics survey. After 3 weeks, 55 surveys were completed, and the data were analyzed. Descriptive statistics were generated as well as a logistic regression with five potential predictor variables against the outcome variable (defined as use of naltrexone for AUD patients).Results:Years practicing as an APRN was found to negatively predict naltrexone prescribing behavior for AUD patients. Practice setting and work experience with an addiction specialist physician were not found to predict naltrexone prescribing behavior for AUD patients.Conclusion:Implications for further study were discussed, with emphasis on regulatory variance between states. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the American Psychiatric Nurses Association SAGE

Understanding Ohio X-Waivered Advanced Practice Registered Nurses’ Rate of Naltrexone Prescription for Alcohol Use Disordered Patients

Download PDF
11 pages

Loading next page...
 
/lp/sage/understanding-ohio-x-waivered-advanced-practice-registered-nurses-rate-AaXYExqxSg
Publisher
SAGE
Copyright
© The Author(s) 2023
ISSN
1078-3903
eISSN
1532-5725
DOI
10.1177/10783903221151062
Publisher site
See Article on Publisher Site

Abstract

Background:Alcohol use disorder (AUD) is overrepresented within the United States. Naltrexone, a recommended treatment for AUD, is underutilized. However, the prescribing behaviors of advanced practice registered nurses (APRNs) regarding naltrexone for AUD patients have not been studied. The purpose of our study was to explore the prescriptive practices of a sample of APRNs.Aims:To describe and analyze survey responses of a sample of Ohio APRNs with training in medication for addiction treatment (MAT) for substance use disorders (as evidenced by DEA x-waiver receipt) regarding prescribing practices of naltrexone for AUD patients.Method:Public information collected from the first author’s Nursing Board (list of APRNs in Ohio) was checked against the public information of x-waivered providers nationally from the Substance Abuse and Mental Health Services Administration’s (SAMHSA) website. This generated a potential sample size of 824 APRNs, all of whom were sent email solicitations to complete a Qualtrics survey. After 3 weeks, 55 surveys were completed, and the data were analyzed. Descriptive statistics were generated as well as a logistic regression with five potential predictor variables against the outcome variable (defined as use of naltrexone for AUD patients).Results:Years practicing as an APRN was found to negatively predict naltrexone prescribing behavior for AUD patients. Practice setting and work experience with an addiction specialist physician were not found to predict naltrexone prescribing behavior for AUD patients.Conclusion:Implications for further study were discussed, with emphasis on regulatory variance between states.

Journal

Journal of the American Psychiatric Nurses Association – SAGE

Published: Jan 1, 2023

Keywords: alcohol use disorder; medication for addiction treatment; APRN prescribing patterns

References

  • Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial
    Anton, R. F.; O’Malley, S. S.; Ciraulo, D. A.; Cisler, R. A.; Couper, D.; Donovan, D. M.; Gastfriend, D. R.; Hosking, H. D.; Johnson, B. A.; LoCastro, J. S.; Longabaugh, R.; Mason, B. J.; Mattson, M. E.; Miller, W. R.; Pettinati, H. M.; Randall, C. L.; Swift, R.; Weiss, R. D.; Williams, L. D.; Zweben, A.
  • Use your words carefully: What is a chronic disease?
    Bernell, S.; Howard, S. W.
  • Response rate differences between web and alternative data collection methods for public health research A systematic review of the literature
    Blumenberg, C.; Barros, A. J. D.
  • Efficacy and safety of oral Naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review
    Bouza, C.; Angeles, M.; Ana, M.; Maria, A. J.
  • These are America’s drunkest states
    Buckingham, C.
  • Paper- or web-based questionnaire invitations as a method for data collections: Cross-sectional comparative study of differences in response rate, completeness of data, and financial cost
    Ebert, J. F.; Huibers, L.; Christensen, B.; Christensen, M. B.
  • Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers
    Harris, A. H.; Ellerbe, L.; Reeder, R. N.; Bowe, T.; Hagedorn, H.; Lembke, A.; Gordon, A. J.; Oliva, E.; Kivlahan, D.; Trafton, J. A.
  • Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: Patterns of receipt and persistence
    Harris, A. H.; Oliva, E.; Bowe, T.; Humphreys, K. N.; Kivlahan, D. R.; Trafton, J. A.
  • The prescription of anticraving medication and its economic consequences
    Holzbach, R.; Stammen, G.; Kirchhof, U.; Scherbaum, N.
  • Use of naltrexone for alcohol use disorders in the Veterans’ Health Administration: A national study
    Iheanacho, T.; Issa, M.; Marienfeld, C.; Rosenheck, R.
  • Burnout among Healthcare professionals during COVID-19 pandemic: A cross-sectional study
    Jalili, M.; Niroomand, M.; Hadavand, F.; Zeinali, K.; Fotouhi, A.
  • Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis
    Jonas, D. E.; Amick, H. R.; Feltner, C.; Bobashev, G.; Thomas, K.; Wines, R.; Kim, M. M.; Shanahan, E.; Gass, C. E.; Rowe, C. J.; Garbutt, J. C.
  • German guidelines on screening, diagnosis and treatment of alcohol use disorders
    Mann, K.; Batra, A.; Fauth-Buhler, M.; Hoch, E.
  • Barriers to the use of medications to treat alcoholism
    Mark, T. L.; Kranzler, H. R.; Poole, V. H.; Hagen, C. A.; McLeod, C.; Crosse, S.
  • Understanding U.S. addiction physicians’ low rate of naltrexone prescription
    Mark, T. L.; Kranzler, H. R.; Song, X.
  • Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications
    Mark, T. L.; Swait, J.
  • Medical treatment of alcohol dependence: A systematic review
    Miller, P. M.; Book, S. W.; Stewart, S. H.
  • The cost-effectiveness of tailored, postal feedback on general practitioners’ prescribing of pharmacotherapies for alcohol dependence
    Navarro, H. J.; Shakeshaft, A.; Doran, C. M.; Petrie, D. J.
  • Barriers to use of pharmacotherapy for addiction disorders and how to overcome them
    Oliva, E. M.; Maisel, N. C.; Gordon, A. J.; Harris, A. H. S.
  • Beyond brief intervention: Pharmacologic management of alcohol use disorder
    Pearson, C.; Duff, E.
  • Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs
    Petrakis, I. L.; Leslie, D.; Rosencheck, R.
  • In search of how people change: Applications to addictive behaviors
    Prochaska, J. O.; DiClemente, C. C.; Norcross, J. C.
  • The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder
    Reus, V. I.; Fochtmann, L. J.; Bukstein, O.; Eyler, A. E.; Hilty, D. M.; Horvitz-Lennon, M.; Mahoney, J.; Pasic, J.; Weaver, M.; Wills, C. D.; McIntyre, J.; Kidd, J.; Yager, J.; Hong, S.
  • Opioid antagonists for alcohol dependence (Review)
    Rosner, S.; Hackl-Herrwerth, A.; Leucht, S.; Vecchi, S.; Srisurapanont, M.; Soyka, M.
  • Very low frequency of drug therapy of alcohol dependence in Germany—Analysis of data of a statutory health insurance
    Scherbaum, N.; Holzbach, R.; Stammen, G.; Kirchof, U.; Bonnet, U.
  • Recent developments in pharmacotherapy of alcoholism
    Soyka, M.; Lieb, M.
  • New pharmacological treatment strategies for relapse prevention
    Spanagel, R.; Vengeliene, V.
  • How telehealth care exploded due to COVID: What nurse researchers need to know
    Spaulding, R.; Smith, C. E.
  • First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario
    Spithoff, S.; Turner, S.; Gomes, T.; Martins, D.; Singh, S.
  • Research to practice: Adoption of Naltrexone in alcoholism treatment
    Thomas, C. P.; Wallack, S. S.; Lee, S.; McCarty, D.; Swift, R.